Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2025-08-09 07:00 GMT | Update On 2025-08-09 07:00 GMT

New Delhi: Eli Lilly and Company (India) Pvt Ltd has secured regulatory clearance from the Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) for updating the package insert of its drug Ixekizumab Solution for Injection 80 mg/mL, in both pre-filled autoinjector and pre-filled syringe formats.

The approval pertains to Package Insert Version 2 dated November 2024, incorporating changes in the sections of Special Warnings and Precautions for Use, Undesirable Effects, Post-Marketing Experience, and Patient Counselling Information. These updates are aligned with the USFDA package insert update approval dated 20th August 2024.

The matter was reviewed during the SEC (Dermatology & Allergy) meeting held on 23rd July 2025 at CDSCO headquarters, New Delhi. After detailed deliberation, the committee “recommended for approval of updated package insert Version 2 dated November 2024 of the said drug product for the proposed changes.”

Ixekizumab, a monoclonal antibody, works by selectively binding to interleukin-17A (IL-17A), a pro-inflammatory cytokine involved in the pathogenesis of psoriasis and psoriatic arthritis. The drug is indicated for the treatment of moderate-to-severe plaque psoriasis in patients who may benefit from phototherapy or systemic therapy, and for active psoriatic arthritis, either alone or in combination with other disease-modifying agents such as methotrexate.

Also Read: Pfizer Gets Expert Panel Nod to Update Etanercept Pre-Filled Injection Label

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Dr. Divya Colin

Dr. Divya Colin, a Doctor of Pharmacy Graduate with extensive experience in clinical and hospital settings and confidently equipped with diagnostic and therapeutic skills. She also has spread out exposure to Oncology Departments in Mysore Medical College and Research Institute as Oncology Pharmacist. Currently she is building a career in clinical research and clinical data management. She has been a part of Medical Dialogue since January 2022.

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Eli Lilly Gets CDSCO Panel Nod for Ixekizumab Safety Label Update

Similar News

Syneos Health Asked to Clarify Phase II Tacrolimus Trial Protocol by CDSCO Panel

Zydus Lifesciences Gets CDSCO Panel Nod for Bioavailability Study of Antimalarial Candidate ZY-19489

CDSCO Panel Asks Astellas Pharma to Update Enzalutamide Label After Phase IV Study

Intas Pharma Told to Revise Phase I, III Pembrolizumab Trial Protocol

CDSCO Panel Asks Akums for Detailed Data on Phase III Eye Drop Trial

CDSCO Panel Flags Trial Death, Seeks Causality Report from Reliance Life Sciences on EtanerRel

Spurious Drugs Alert: Diazepam, PAN 40, and PAN-D Capsules Under Investigation

Biocon Gets CDSCO Panel Nod to Import Aflibercept Injection for Eye Disorders, Phase IV Trial Mandated